Dr. Reddy's Laboratories Ltd. (DRREDDY) Price & Analysis

Compare

5 Followers

DRREDDY Stock Chart & Stats

₹1235.95

₹4.55(0.33%)

At close: Jan 09 4:00 PM EST

₹1235.95

₹4.55(0.33%)

Day’s Range― - ―

52-Week Range₹1,025.90 - ₹1,404.60

Previous CloseN/A

Volume1.21M

Average Volume (3M)225.11K

Market Cap

₹1.00T

Enterprise Value₹1.06T

Total Cash (Recent Filing)₹66.69B

Total Debt (Recent Filing)₹48.64B

Price to Earnings (P/E)17.1

Beta0.75

Next Earnings

Jan 23, 2026

EPS Estimate

14.86

Last Dividend Ex-Date

Jul 10, 2025

Dividend Yield0.65%

Share Statistics

EPS (TTM)17.30

Shares Outstanding834,574,700

10 Day Avg. Volume499,682

30 Day Avg. Volume225,111

Financial Highlights & Ratios

PEG Ratio11.98

Price to Book (P/B)2.88

Price to Sales (P/S)2.95

P/FCF Ratio50.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,350.00

Price Target Upside9.23% Upside

Rating ConsensusHold

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Dr. Reddy's Laboratories Ltd. News

Dr. Reddy’s Laboratories Releases Q2 FY26 Earnings Call Transcript

The latest update is out from Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ). Dr. Reddy’s Laboratories Ltd. has...

28d ago

Dr. Reddy’s Laboratories Receives Positive FDA Inspection Outcome

Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ) has issued an announcement. Dr. Reddy’s Laboratories Ltd. announced that the...

1M ago

No jobs report amid shutdown, Apple pulls ICEBlock from App Store: Morning Buzz

The major averages were sharply higher near noon as the U.S. government shutdown marks its third day. There...

2M ago

Esperion reaches settlement agreement with ANDA filer, Dr. Reddy’s

Esperion (ESPR) announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories (RDY) and its...

2M ago

RDY

ESPR

Dr. Reddy’s Laboratories Ensures Compliance with SEBI Regulations

The latest update is out from Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ). Dr. Reddy’s Laboratories Ltd. has...

2M ago

Alvotech says CHMP adopts positive opinion for AVT03

Alvotech (ALVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human use adopted a positive...

2M ago

RDY

ALVO

Dr. Reddy’s, Extrovis launch authorized generic of CARAC in the U.S.

Extrovis and Dr. Reddy’s (RDY) Laboratories announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic...

3M ago

RDY

Dr. Reddy’s Laboratories Releases Q1 FY26 Earnings Call Transcript

The latest update is out from Dr. Reddy’s Laboratories Ltd. ( ($IN:DRREDDY) ). Dr. Reddy’s Laboratories Ltd. has...

4M ago

Alvotech, Dr. Reddy’s enter pact to codevelop biosimilar candidate to Keytruda

Alvotech (ALVO) and Dr. Reddy’s (RDY) announced that the companies have entered into a collaboration and license agreement...

6M ago

RDY

ALVO

Dr. Reddy’s upgraded to Buy from Hold at HSBC

HSBC upgraded Dr. Reddy’s (RDY) to Buy from Hold with a price target of $16.90, up from $14.44....

6M ago

RDY

Dr. Reddy’s Laboratories Ltd. (DRREDDY) Discloses Q3 Dividend: What Shareholders Should Know

Dr. Reddy’s Laboratories Ltd. (NSE: DRREDDY) has declared, under its dividend policy, a yearly cash dividend in the...

7M ago

Dr. Reddy’s says report of 25% workforce cost reduction ‘incorrect’

Dr. Reddy’s (RDY) commented on a news item published in Business Standard on April 13, with the heading...

8M ago

RDY

Dr. Reddy’s says report of 25% workforce cost reduction ‘incorrect’

Dr. Reddy’s (RDY) commuted on a news item published in Business Standard on April 13, with the heading...

8M ago

RDY

Dr. Reddy’s, Alvotech announce FDA acceptance of AVT03 BLA

Dr. Reddy’s (RDY) and Alvotech (ALVO) announced that the FDA has accepted a 351(k) biologic license application submission...

8M ago

RDY

ALVO

DRREDDY FAQ

What was Dr. Reddy's Laboratories Ltd.’s price range in the past 12 months?

Dr. Reddy's Laboratories Ltd. lowest stock price was ₹1025.90 and its highest was ₹1404.60 in the past 12 months.

What is Dr. Reddy's Laboratories Ltd.’s market cap?

Dr. Reddy's Laboratories Ltd.’s market cap is ₹1.00T.

When is Dr. Reddy's Laboratories Ltd.’s upcoming earnings report date?

Dr. Reddy's Laboratories Ltd.’s upcoming earnings report date is Jan 23, 2026 which is in 57 days.

How were Dr. Reddy's Laboratories Ltd.’s earnings last quarter?

Dr. Reddy's Laboratories Ltd. released its earnings results on Oct 24, 2025. The company reported ₹17.3 earnings per share for the quarter, beating the consensus estimate of ₹16.992 by ₹0.308.

Is Dr. Reddy's Laboratories Ltd. overvalued?

According to Wall Street analysts Dr. Reddy's Laboratories Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dr. Reddy's Laboratories Ltd. pay dividends?

Dr. Reddy's Laboratories Ltd. pays a Annually dividend of ₹8 which represents an annual dividend yield of 0.65%. See more information on Dr. Reddy's Laboratories Ltd. dividends here

What is Dr. Reddy's Laboratories Ltd.’s EPS estimate?

Dr. Reddy's Laboratories Ltd.’s EPS estimate is 14.86.

How many shares outstanding does Dr. Reddy's Laboratories Ltd. have?

Dr. Reddy's Laboratories Ltd. has 834,574,700 shares outstanding.

What happened to Dr. Reddy's Laboratories Ltd.’s price movement after its last earnings report?

Dr. Reddy's Laboratories Ltd. reported an EPS of ₹17.3 in its last earnings report, beating expectations of ₹16.992. Following the earnings report the stock price went up 0.324%.

Which hedge fund is a major shareholder of Dr. Reddy's Laboratories Ltd.?

Currently, no hedge funds are holding shares in IN:DRREDDY

Company Description

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Ltd. (DRREDDY) is a global pharmaceutical company based in India, specializing in the development, manufacture, and marketing of a wide range of generic and branded medications. The company operates across various sectors, including pharmaceuticals, active pharmaceutical ingredients (APIs), and biotechnology. DRREDDY's core products include prescription medications across multiple therapeutic areas such as oncology, cardiology, and dermatology, as well as over-the-counter products and biosimilars.

Dr. Reddy's Laboratories Ltd. (DRREDDY) Earnings & Revenues

Historic Earnings Reports

DRREDDY Stock 12 Month Forecast

Average Price Target

₹1,350.00

▲(9.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1109":"₹1,109","1280":"₹1,280","1451":"₹1,451","1194.5":"₹1,194.5","1365.5":"₹1,365.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1450,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.45K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.35K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1250,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.25K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1109,1194.5,1280,1365.5,1451],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1246.25,1261.923076923077,1277.5961538461538,1293.2692307692307,1308.9423076923076,1324.6153846153845,1340.2884615384614,1355.9615384615386,1371.6346153846155,1387.3076923076924,1402.9807692307693,1418.6538461538462,1434.326923076923,{"y":1450,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1246.25,1254.2307692307693,1262.2115384615386,1270.1923076923076,1278.173076923077,1286.1538461538462,1294.1346153846155,1302.1153846153845,1310.0961538461538,1318.076923076923,1326.0576923076924,1334.0384615384614,1342.0192307692307,{"y":1350,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1246.25,1246.5384615384614,1246.826923076923,1247.1153846153845,1247.4038461538462,1247.6923076923076,1247.9807692307693,1248.2692307692307,1248.5576923076924,1248.8461538461538,1249.1346153846155,1249.423076923077,1249.7115384615386,{"y":1250,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1340.89,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1266.22,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1213.75,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1213.75,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1360.87,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1110.61,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1145.14,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1175.54,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1241.23,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1268.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1219.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1280.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1246.25,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >